Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

ConclusionsThe current findings are consistent with previously reported trials and confirm the safety profile of daratumumab in heavily pretreated US patients who have relapsed or refractory MM.Cancer 2018;124:000 ‐000.

Source: Cancer - November 5, 2018 Category: Cancer & Oncology Authors: Ajai Chari, Sagar Lonial, Tomer M. Mark, Amrita Y. Krishnan, Keith E. Stockerl ‐Goldstein, Saad Z. Usmani, Anil Londhe, Delores Etheredge, Sarah Fleming, Baolian Liu, Jon Ukropec, Thomas S. Lin, Sundar Jagannath, Ajay K. Nooka Tags: Original Article Source Type: research